The Immunohistochemical Study of Stathmin-1 as A Prognostic factor In Non-small cell lung carcinoma
DOI:
https://doi.org/10.32007/jfacmedbagdad.6441948Keywords:
Stathmin-1, Lung Cancer.Abstract
Background
Stathmin1 (also known as metablastin) is a major microtubule-depolymerizing protein that involved in cell cycle progression and cell motility.
Stathmin1 has been found to be up-regulated in some cancers and correlated with cell differentiation and proliferation.
Stathmin1 is a major cytosolic phosphoprotein that regulates microtubule dynamics and is associated with malignant phenotypes in various cancers, including non-small cell lung cancer.
Objective
To evaluate the role of Immunohistochemical expression of stathmin1 in non-small lung carcinoma and its correlation to different prognostic factors or parameters.
Materials and methods
This retrospective study carried on formalin fixed paraffin embedded surgical specimens of lung tumors Applying the Immunohistochemical techniques by using the primary antibodies to stathmin1, statistical analysis done and assessment of correlation with different clinical and pathological parameters measured.
Results
Fifty cases of Non-small lung carcinomas that 42% adenocarcinoma,44% squamous cell carcinoma 10% adenosequamous and 4% non-small lung carcinoma 84 % were Stathmin-1 positive.
No significant correlation between Stathmin-1 expression with age and gender of patients but Stathmin-1 expression were correlated with parameters including type and grade of tumor.
High expression was noted in poorly differentiated tumors.
Conclusions
Measurement of stathmin1 level may be a beneficial prognostic biomarker for non-small lung tumors especially those of poorly differentiated tumors
Stathmin1 expression in non-small cell lung carcinoma significantly correlated with poor tumor differentiation and could be considered as independent prognostic factor.
Downloads
References
Ferlay j, Soerjomataram I,Ervic M,Dikshit R,Eser S,
MathersC et al. Globocan2012v1.0,Cancer Incidence
and Mortality Worldwide:IARC CancerBase No.11.
Yoshizawa A, Motoi N, Riely GJ, et al. Impact of
proposed IASLC/ATS/ERS classification of lung
adenocarcinoma: prognostic subgroups and
implications for further revision of staging based on
analysis of 514 stage I cases. Mod Pathol.
;24(5):653-664.
Iancu-Rubin C, Nasrallah CA, Atweh GF. Stathmin
prevents the transition from a normal to an endomitotic
cell cycle during megakaryocytic differentiation. Cell
Cycle (Georgetown, Tex) 2005;4(12):1774-82.
Alli E, Yang JM, Hait WN. Silencing of stathmin
induces tumor-suppressor function in breast cancer cell
lines harboring mutant p53. Oncogene
;26(7):1003-12 17.
Mistry SJ, Benham CJ, Atweh GF. Development of
ribozymes that target stathmin, a major regulator of the
mitotic spindle. Antisense Nucleic Acid Drug Dev
;11(1):41-9 .
Yuan RH, Jeng YM, Chen HL, et al. Stathmin
overexpression cooperates with p53 mutation and
osteopontin overexpression, and is associated with
tumour progression, early recurrence, and poor
prognosis in hepatocellular carcinoma. J Pathol 2006;
:549–558.
Biaoxue R, Liu Hua, Fu Tian, Gao Wenlong,
Increased stathmin in serum as a potential tumor
marker for lung adenocarcinoma. Japanese Journal of
Clinical Oncology, Volume 47, Issue 4, April 2017,
–349.
Immunohistochemical Study of Stathmin-1 as A Prognostic factor In Nadhema B. Hussein
Non-small cell lung carcinoma.
J Fac Med Baghdad 202 Vol.64 No. 4, 2022
Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D,
Higo M, et al. Overexpression of stathmin in oral
squamous-cell carcinoma: correlation with tumour
progression and poor prognosis. Br J Cancer. 2006;94:
-23.
Belletti B, Baldassarre G. Stathmin: a protein with
many tasks. New biomarker and potential target in
cancer. Expert Opin Ther Targets. 2011; 15:1249-66.
Yurong L, Rong Biaoxue, Li Wei et al. Stathmin
overexpression is associated with growth, invasion and
metastasis of lung adenocarcinoma: Oncotarget. 2017;
:16 ,26000-26012.
Biaoxue R, Increased stathmin in serum as a
potential tumor marker for lung adenocarcinoma.
Japanese Journal of Clinical Oncology. 2017; 7: 47
-668.
Shimizu K. Prognostic impact of stathmin 1
expression in patients with lung adenocarcinoma. The
Journal of Thoracic and Cardiovascular Surgery.
:4,154, 1406-1417.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 PROFESSOR : MUHAMMED WAHEEB SALMAN AL,OBAIDY, Dr. Nadhema Bahaa Hussein Wetwet, Dr. Hadeel Abdulelah Karbel KERBEL, Dr.Ali Salih Baay Baay
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.
How to Cite
Creative Commons Attribution 4.0 International license..
